Navigation Links
First antibiotic stewardship probed in the Journal of the Pediatric Infectious Diseases Society
Date:8/9/2012

ARLINGTON, VA, August 9, 2012The Journal of the Pediatric Infectious Diseases Society (JPIDS) today released the largest and most rigorous evaluation to date of the impact on reducing the days of antibiotic therapy in a children's hospital using a prospective-audit-with-feedback antibiotic stewardship program (ASP). The study utilized a control group of the 25-member children's hospitals of the Child Health Corporation of America. A companion article describes how the ASP was created within this 317-bed tertiary care children's hospital and clinicians' attitudes toward itthe first published account of such a pediatric program.

Up to 35% of inpatient antibiotic prescriptions are either unnecessary or inappropriate. The Infectious Diseases Society of America's (IDSA) 2007 guideline on the implementation of hospital ASPs described two core stewardship strategies to curb the rise of drug-resistant microbes: prospective-audit-with-feedback, and preauthorization. IDSA said that research would be needed to determine whether these strategies would be effective in pediatrics.

In this more-than-33-month study of 8,765 patients, Newland et al, observed a significant decrease in antibiotic usageranging from a 37% decrease in the early months, to 13% at the end of the observation. In particular, the study showed up to a 19% monthly reduction in broad-spectrum antibiotics, which the Centers for Disease Control and Prevention have recommended avoiding in order to prevent resistance in hospitalized children.

In the companion article, Stach et al, describe the five-part process they used to create their ASP, including: forming a multi-disciplinary team; determining the type of program (prospective-audit-with-feedback) and which antimicrobials to monitor; deciding which mechanism to use in identifying patients (a report was created in the hospital's EMR system); developing and implementing an evaluation process; and, communicating the goals and logistics of the ASP to the hospital's affected clinicians.

The authors surveyed 365 clinicians; the 56% who responded had a positive view of the ASP. The overwhelming majority agreed that the ASP had improved the use (83%) of antibiotics, decreased their inappropriate use (84%), and improved the quality of patient care (82%). An ASP goal was to provide education to those affected by the program; 90% said it did and 66% agreed it led to practice changes. Of negative feelings, only 6% felt the ASP interfered with clinical decision-making and 5% thought the ASP's recommendations were threatening.


'/>"/>
Contact: Jodie Klein
jodieklein@kleinonpoint.com
703-528-3333
Pediatric Infectious Diseases Society
Source:Eurekalert

Related biology news :

1. Kessler Foundation implements Ekso Bionics first commercial robotic exoskeleton
2. Research reveals first evidence of hunting by prehistoric Ohioans
3. First model of how buds grow into leaves
4. American College of Rheumatology releases first classification criteria for polymyalagia rheumatica
5. Ottawa researchers to lead world-first clinical trial of stem cell therapy for septic shock
6. First complete full genetic map of promising energy crop
7. FirstMark Announces New Hire Jay Houtman as Southeast Regional Sales Manager
8. FirstMark Exhibiting at the Inaugural Atlanta Clinical Cardiology Update
9. New technology tracks sparrow migration for first time from California to Alaska
10. First mass extinction linked to marine anoxia
11. Scientists complete first-ever emperor penguin count from space
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/2/2017)... JACKSONVILLE, Fla. , Feb. 2, 2017 /PRNewswire/ ... ), a clinical-stage immuno-oncology company specializing in the ... vaccines for the treatment of cancer and metastatic ... multi-gram scale-up and GMP manufacturing of a second ... T-cell vaccine targeting folate receptor alpha. The manufactured ...
(Date:2/2/2017)... , Feb. 1, 2017  Central to its ... meaningful advances worldwide, The Japan Prize Foundation today ... who have pushed the envelope in their respective ... Communication. Three scientists are being recognized with the ... that not only contribute to the advancement of ...
(Date:1/31/2017)... Jan. 31, 2017  Spero Therapeutics, LLC, a ... the treatment of bacterial infections, today announced it ... candidates from Pro Bono Bio Ltd (PBB) to ... multi-drug resistant forms of Gram-negative bacteria.   The assets ... Ltd, a PBB group company. "The ...
Breaking Biology News(10 mins):
(Date:2/16/2017)... HACKENSACK, N.J. , Feb. 16, 2017  Champions ... engaged in the development and sale of advanced technology ... of oncology drugs, today announced the addition of new ... These new models will expand Champions, product ... cancer, head and neck cancer, AML, and non-small cell ...
(Date:2/16/2017)... and NEW YORK , Feb. 16, ... completion of their $7M Series B financing, adding an ... the $3.5M led by Mesa Verde Venture Partners and ... resources will be directed towards further accelerating commercial adoption ... comprehensive genomic profiling test and expanding the Paradigm cancer ...
(Date:2/15/2017)... , 15. Februar 2017  Trianni, Inc. ... Biotech, Inc. (Janssen) eine Lizenzvereinbarung über die Verwendung ... Klasse führenden Plattform für die Entdeckung monoklonaler Antikörper. ... ihr neuartiges chimäres Gensegmentdesign aus, das Janssen ... humanen Antikörpern bietet und das für die schelle ...
(Date:2/15/2017)... -- Windtree Therapeutics, Inc. (Nasdaq: WINT ), ... therapies for respiratory diseases, will host a conference call ... EST on Thursday, February 16, 2017 to provide updates ... announced closing of a $10.5 million private offering and ... in the live call and take part in the ...
Breaking Biology Technology: